MSB 4.69% $1.45 mesoblast limited

High chance fund raising, page-18

  1. 2 Posts.
    See 'Latest stock talk seeking alpha...', by TRIHRD.
    Bad news and could be expected with MSB.
    See same stories recently with Cellceutix and Ocata Therapeutics (both NASDAQ): rich portef. low cash and stock price. Very vulnerable mix.
    Cellceutix got a law suit and Ocata got a takeover.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.